CPC A61B 5/14546 (2013.01) [A61B 5/145 (2013.01); A61B 5/14507 (2013.01); A61B 5/15 (2013.01); A61B 5/4836 (2013.01); A61B 8/08 (2013.01); A61B 8/5223 (2013.01); A61B 10/0038 (2013.01); A61B 10/007 (2013.01); A61N 7/022 (2013.01); C12Q 1/6886 (2013.01); A61B 2010/0077 (2013.01); A61N 7/02 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] | 18 Claims |
1. A system for treating a human patient, the system comprising:
an ultrasound source configured to deliver high intensity focused ultrasound energy to a target tissue mass of the patient;
a function generator operably coupled to the ultrasound source, wherein the function generator initiates a pulsing protocol for delivering the high intensity focused ultrasound energy from the ultrasound source to the target tissue mass; and
a controller in communication with the ultrasound source and the function generator, wherein controller is configured to perform operations comprising—
applying high intensity focused ultrasound energy having a pulse average intensity of between 25 kW/cm2 and 60 k W/cm2 to generate shock waves that induce cavitation in the target tissue mass, the shock waves having a peak positive amplitude of between 78 MPa and 100 MPa, and wherein the cavitation induced by the shock waves causes a biomarker to be released from within cells of the patient;
comparing (a) a baseline concentration of the biomarker from a first fluid sample of the patient to (b) a concentration of the biomarker in a second fluid sample of the subject within 1 hour after applying high intensity focused ultrasound energy to the target tissue mass; and
repeating the applying and comparing until the concentration of the biomarker in the second fluid sample falls below a threshold value.
|